# Quantum Money Already in Price — May 22, 2026
*Your daily premarket briefing, brought to you by [SignalDeck.live](https://signaldeck.live).*
The headline gappers this morning are loud and the volume is whisper-quiet. **TTM Technologies** is the cleanest setup of the lot — relative strength in the top 17% of the universe, +37% on the month going into next week’s Investor Day, with a Q1 beat already on the board. Last night’s big catalyst was the $2B Federal Quantum Initiative announcement (governments taking 15% equity stakes in nine quantum names), but the obvious beneficiaries — Rigetti and GlobalFoundries — are both below our gap gate this morning, suggesting the quantum money is already in price.
## The Top Calls
- **TTMI (TTM Technologies)** · Electronic Components · Gap +10.50% · EP-β 48 — Relative strength rank 83 (top of its universe), month +37.81%, Q1 already beat (+11.94% EPS, +7.11% revenue), and Investor Day on May 27 is a built-in continuation catalyst. The premarket volume is light at 6.4% of an average day, so the standard discipline applies: confirm first-hour gap-hold before sizing. If TTMI opens flat or higher and the regular session bids it up, the Investor Day positioning is real. If it fades from open, it’s the elevated-bar fade — sit it out.
- **HLIT (Harmonic)** · Communication Equipment · Gap +12.20% · EP-β 64 — Continuation from the May 11 Q1 print (+45% EPS surprise, +17% revenue, raised broadband guide to $475–$495M, backlog +87% YoY). The fundamentals are real but the move is happening 10 days after the print, which is past the normal second-entry window. No fresh catalyst surfaced in our search. STRONG on paper, watch-only on practice — unless overnight news clarifies the move, this is a sympathy gap.
- **INFQ (Infleqtion)** · Software-Infrastructure · Gap +8.44% · EP-β 40 — The federal quantum grant winner with confirmed premarket volume (45% of an average day, by far the strongest in the alert). Quantum gets $100M plus a NASA deal and a 15% discount equity stake from the government. But the stock was already up 31% yesterday and is gapping another 8% on top — that’s the textbook elevated-bar setup, where every long who wanted in is already in. The grant is the news; the move was the trade.
> **Risk callout:** Universal volume failure on the Top Calls. PM is very early Friday before the long weekend. Almost every stock will need first-hour open-volume confirmation to justify the premarket gap. Mechanical rule: if Change-from-Open is ≤ -3% by 10:30 ET, it’s a distribution day regardless of the headline number.
## The Quiet Beats
No clean quiet beats passed the filter today. The two real Thursday-AMC earnings (Workday and Zoom) both cooled overnight — Workday gave back nearly four percentage points from its after-hours +10.55% gap, Zoom gave back one. The mega-cap structural-raise template (Workday’s first quarter under a new CEO, FY27 guide +12-13%) only works when the gap holds; today it didn’t. The institutional excitement around the FY27 guide was less than the headline suggested.
> **Pattern note:** When a “clean” AMC earnings gap evaporates overnight, the print was less interesting than the initial reaction suggested. Workday and Zoom both got marked down in extended hours. Recalibrate at the open before committing.
## Yesterday’s Lessons
- **The quantum-grant theme — fast-money phase complete.** Rigetti and GlobalFoundries both ran 30%+ yesterday on the $2B federal initiative; this morning they’re both gapping less than 6%, below our gate. That’s the signature of a catalyst whose obvious play already happened. Future quantum trades need to come from the second-derivative names (smaller cap, less-followed) or wait for the next data point — not chase the leaders.
- **Designs Therapeutics (DSGN) — clinical-catalyst distribution day still firing.** RS collapsed from 82 to 4 since the Monday readout, week -24%. The first-hour gap-hold check would have saved the entry; the headline positive Phase 1/2 result was the gap, and the regular session was institutions exiting. Mandatory check is now table stakes for any clinical-readout setup.
- **Cisco — multi-day structural raise template, second confirmed instance.** Entered last week at top-3% RS on the FY26 guide raise + restructuring. Today RS 85, month +32%. Mid-band D5 target captured. The AMD May 5 playbook now has its second clean confirmation: mega-cap raises FY guide on a structural narrative, hold for days, not minutes.
## The Read
**Best risk-adjusted trade today:** **TTMI** — high relative strength, real Q1 beat already booked, next week’s Investor Day as the forward catalyst. Discipline: confirm first-hour open-volume before sizing. D5 target +5-10%, D15 +10-18% if the Investor Day extends the narrative.
**Highest-upside speculative trade:** None tonight has clean upside. INFQ has the volume confirmation but the gap is on a catalyst the market already priced in yesterday. EWTX (Edgewise) has biotech clinical-catalyst optionality but premarket volume is essentially absent (0.14% of average), making it un-tradeable from premarket. Wait.
**Best two-week compounding trade:** **HLIT** — conditional on a fresh catalyst surfacing today. The May 11 Q1 fundamentals (clean blowout, raised guide, +87% backlog) are still in place. If a fresh contract or partnership news drops, the setup compounds. If not, the Day-10 surge fades.
**Don’t chase:** **IMAX** (M&A speculation per WSJ — bounded by deal premium if confirmed, classic arb dynamic, not momentum). **EL** (Estée Lauder gap unexplained, three-week-old print, May 29 dividend positioning at best). **EWTX** (no volume, no fresh data, pre-positioning before unknown clinical readout).
**Lesson banked:** When the headline gappers have universally thin premarket volume, the framework’s volume gate is doing its job — preventing recommendation of moves that aren’t backed by institutional flow. Today no stock got a STRONG tag. That’s a feature, not a bug. The right action on a thin-volume Friday before a long weekend is to wait for the open to clarify, not to chase the gap percentages.
---
**Not financial advice.** This is independent market analysis and momentum research, not a recommendation to buy or sell anything. Markets are volatile, individual securities can lose 100% of their value, and past performance does not predict future results. Do your own due diligence, size positions you can afford to lose, and consult a licensed financial advisor before making investment decisions. Your money, your risk, your call.